NeuroKaire Enters Into R&D Collaboration With Compass Pathways To Pioneer Precision Treatments For Depression

NeuroKaire, which specializes in precision psychiatry and neurology, announced a research and development (R&D) collaboration with Compass Pathways, a biotechnology company dedicated to transforming mental health care. The goal of the partnership is to deepen the mechanistic understanding of psychedelic compounds by testing the structure of, and connectivity between, neurons (brain cells) using patient-derived neurons with known clinical phenotypes. The study will make use of stem cell-derived neurons from individuals with treatment-resistant depression (TRD) and major depressive disorder (MDD).

The planned study leverages NeuroKaire's proprietary platform, which applies cutting edge biology and AI-powered . . .